Objectives To define the prognostic contribution of global and regional left ventricular (LV) function measurements in patients with ischaemic cardiomyopathy randomised to coronary artery bypass graft surgery (CABG) with (n=501) or without (n=499) surgical ventricular reconstruction (SVR).
Methods Novel multivariable methods to analyse global and regional LV systolic function were used to better formulate prediction models for long-term mortality following CABG with or without SVR in the entire cohort of 1000 randomised SVR hypothesis patients. Key clinical variables were included in the analysis. Regional function was classified according to the discreteness of anteroapical hypokinesia and akinesia into those most likely to benefit from SVR, those least likely and those felt to have intermediate likelihood of benefit from SVR.
Results The most prognostic clinical variables identified in multivariable models include creatinine, LV end-systolic volume index (ESVI), age and NYHA (New York Heart Association) class. Addition of LV ejection fraction, LV end-diastolic volume index and regional function assessment did not contribute additional power to the model. Subgroup analysis based on regional function did not identify a cohort in which SVR improved mortality.
Conclusions ESVI is the single parameter of LV function most predictive of mortality in patients with LV systolic dysfunction following CABG with or without SVR in multivariable models that include all key clinical and LV systolic function parameters. Assessment of regional cardiac function does not enhance prediction of mortality nor identify a subgroup for which SVR improves mortality. These results do not support elective addition of LV reconstruction surgery in patients undergoing CABG.
Trial registration number NCT00023595.
- randomised clinical trial
- coronary artery bypass grafting
- ischaemic cardiomyopathy
- surgical ventricular reconstruction
- end-systolic volume index
Statistics from Altmetric.com
Funding This work was supported by Grants U01-HL69015, U01-HL69013 and R01-HL105853 from the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Competing interests DSB participates in royalties to Cedars-Sinai for the software used for some of the SPECT analysis.
Provenance and peer review Not commissioned; externally peer reviewed.
Correction notice Since this article was published online an update has been made to a grant number and the STICH trial investigators have been added in the author list.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.